JP2015519890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519890A5 JP2015519890A5 JP2015509079A JP2015509079A JP2015519890A5 JP 2015519890 A5 JP2015519890 A5 JP 2015519890A5 JP 2015509079 A JP2015509079 A JP 2015509079A JP 2015509079 A JP2015509079 A JP 2015509079A JP 2015519890 A5 JP2015519890 A5 JP 2015519890A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- natural killer
- culturing
- item
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 63
- 210000000130 stem cell Anatomy 0.000 claims description 33
- 210000000822 natural killer cell Anatomy 0.000 claims description 32
- 238000012258 culturing Methods 0.000 claims description 29
- 239000012679 serum free medium Substances 0.000 claims description 29
- 210000002242 embryoid body Anatomy 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 8
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 8
- 108090000172 Interleukin-15 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000646 Interleukin-3 Human genes 0.000 claims description 8
- 108010002386 Interleukin-3 Proteins 0.000 claims description 8
- 102000000704 Interleukin-7 Human genes 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 102000002698 KIR Receptors Human genes 0.000 claims description 8
- 108010043610 KIR Receptors Proteins 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 229940076264 interleukin-3 Drugs 0.000 claims description 8
- 229940100994 interleukin-7 Drugs 0.000 claims description 8
- 210000002536 stromal cell Anatomy 0.000 claims description 8
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 7
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 7
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 102100039564 Leukosialin Human genes 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 238000003501 co-culture Methods 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 4
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102000036366 SCF complex Human genes 0.000 claims description 4
- 108091007047 SCF complex Proteins 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 230000004931 aggregating effect Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637592P | 2012-04-24 | 2012-04-24 | |
| US61/637,592 | 2012-04-24 | ||
| PCT/US2013/037782 WO2013163171A1 (en) | 2012-04-24 | 2013-04-23 | Method for developing natural killer cells from stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017115944A Division JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519890A JP2015519890A (ja) | 2015-07-16 |
| JP2015519890A5 true JP2015519890A5 (OSRAM) | 2016-06-23 |
| JP6339998B2 JP6339998B2 (ja) | 2018-06-06 |
Family
ID=48289670
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509079A Active JP6339998B2 (ja) | 2012-04-24 | 2013-04-23 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2017115944A Active JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2019091121A Pending JP2019122415A (ja) | 2012-04-24 | 2019-05-14 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017115944A Active JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2019091121A Pending JP2019122415A (ja) | 2012-04-24 | 2019-05-14 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9260696B2 (OSRAM) |
| EP (2) | EP3567102A1 (OSRAM) |
| JP (3) | JP6339998B2 (OSRAM) |
| AU (3) | AU2013251785B2 (OSRAM) |
| WO (1) | WO2013163171A1 (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260696B2 (en) * | 2012-04-24 | 2016-02-16 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP6773268B2 (ja) * | 2015-03-09 | 2020-10-21 | 学校法人慶應義塾 | 多能性幹細胞を所望の細胞型へ分化する方法 |
| CN105517672B (zh) * | 2015-05-26 | 2019-06-21 | 中国科学院广州生物医药与健康研究院 | 一种人原代细胞培养基及其应用 |
| PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| CN107850596B (zh) * | 2015-07-24 | 2020-12-04 | 先天制药公司 | 用于检测组织浸润nk细胞的方法 |
| ES2922475T3 (es) * | 2015-09-08 | 2022-09-15 | Sumitomo Pharma Co Ltd | Método para producir células epiteliales pigmentarias de la retina |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN105296428A (zh) * | 2015-12-03 | 2016-02-03 | 广州医科大学附属第三医院 | 一种提高诱导多能干细胞的体外分化造血效率的方法 |
| JP2019505498A (ja) | 2015-12-16 | 2019-02-28 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害 |
| US20190161726A1 (en) * | 2016-07-29 | 2019-05-30 | Daikin Industries, Ltd. | Differentiated cell production method and culture bag used therefor |
| US20190194621A1 (en) * | 2016-09-08 | 2019-06-27 | Kyowa Hakko Bio Co., Ltd. | Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same |
| JP7092281B2 (ja) * | 2017-02-07 | 2022-06-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット |
| US11696927B2 (en) * | 2017-02-28 | 2023-07-11 | University Of Central Florida Research Foundation, Inc. | PM21 particles to improve bone marrow homing of NK cells |
| CN110573610B (zh) | 2017-03-08 | 2025-01-28 | 住友制药株式会社 | 视网膜色素上皮细胞的制备方法 |
| US20200080058A1 (en) * | 2017-03-21 | 2020-03-12 | Etablissement Francais Du Sang | Methods of improving hematopoietic grafts |
| KR102167548B1 (ko) * | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| AU2019215034C1 (en) | 2018-02-01 | 2022-01-06 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| FI3755347T3 (fi) * | 2018-02-21 | 2025-07-29 | Univ Texas | Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä |
| SG11202101204TA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Processes for generating engineered cells and compositions thereof |
| WO2020037303A1 (en) | 2018-08-16 | 2020-02-20 | The Regents Of The University Of California | Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof |
| RS65658B1 (sr) | 2018-08-27 | 2024-07-31 | Affimed Gmbh | Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela |
| AU2019336221B2 (en) | 2018-09-07 | 2025-05-15 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| WO2020180744A1 (en) * | 2019-03-01 | 2020-09-10 | The Regents Of The University Of California | Natural killer cell induced cellular vesicles for cancer therapy |
| KR102298639B1 (ko) * | 2019-03-28 | 2021-09-07 | 한국생명공학연구원 | 면역세포의 제조방법 및 그의 용도 |
| RU2731293C1 (ru) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний |
| US20220154144A1 (en) * | 2019-04-26 | 2022-05-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy |
| WO2021096218A1 (ko) | 2019-11-13 | 2021-05-20 | 연세대학교 산학협력단 | 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 |
| CN111235105B (zh) * | 2020-03-06 | 2021-08-10 | 安徽中盛溯源生物科技有限公司 | 一种从人多能干细胞分化为自然杀伤细胞的方法及应用 |
| CN116018148A (zh) * | 2020-03-11 | 2023-04-25 | 全国儿童医院研究所 | Nk细胞及其用于治疗微生物感染的用途 |
| US11547726B2 (en) | 2020-03-26 | 2023-01-10 | Honed Life Sciences, Llc | Enhancement of production of NK cells from stem cells |
| EP4170020A4 (en) | 2020-06-17 | 2025-01-22 | Kyoto University | IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION |
| AU2021317752A1 (en) * | 2020-07-27 | 2023-03-02 | Stemcell Technologies Canada Inc. | Systems and methods for differentiating hematopoietic cells |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| CN112608895B (zh) * | 2020-12-18 | 2024-02-27 | 深圳市济因生物科技有限公司 | 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用 |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| EP4326852A4 (en) * | 2021-04-22 | 2025-04-23 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
| WO2022269393A1 (en) | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| CN115261318B (zh) * | 2021-09-29 | 2024-05-28 | 苏州艾凯利元生物科技有限公司 | 产生自然杀伤细胞的方法 |
| US20250000974A1 (en) * | 2021-10-27 | 2025-01-02 | The Regents Of The University Of California | Combination of human natural killer cells and macrophages for cancer therapy |
| CN113957048A (zh) * | 2021-10-29 | 2022-01-21 | 深圳市默赛尔生物医学科技发展有限公司 | 一种利用脐带血单个核细胞生产自然杀伤细胞的方法 |
| JP2025500894A (ja) | 2021-12-17 | 2025-01-15 | ウモジャ バイオファーマ インコーポレイテッド | 細胞傷害性自然リンパ球系細胞およびその使用 |
| US20250122474A1 (en) * | 2022-01-31 | 2025-04-17 | Healios K.K. | Production method for natural killer cells |
| CN114507641B (zh) * | 2022-04-20 | 2022-07-12 | 山东兴瑞生物科技有限公司 | 一种由人胚胎干细胞诱导分化为nk细胞的方法 |
| WO2023233342A2 (en) | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2023285113A1 (en) * | 2022-06-09 | 2024-12-12 | Umoja Biopharma, Inc. | Compositions and methods for nk cell differentiation |
| CN115058387B (zh) * | 2022-06-11 | 2023-12-01 | 重庆医科大学 | 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法 |
| EP4562133A1 (en) * | 2022-07-27 | 2025-06-04 | Umoja Biopharma, Inc. | Differentiation of stem cells in suspension culture |
| WO2024101862A1 (ko) * | 2022-11-07 | 2024-05-16 | 마루테라퓨틱스 주식회사 | Nk 세포의 분화 효율 및 기능성 증가를 위한 배양 방법 |
| WO2024101863A1 (ko) * | 2022-11-07 | 2024-05-16 | 마루테라퓨틱스 주식회사 | 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법 |
| KR20240069648A (ko) * | 2022-11-10 | 2024-05-20 | 의료법인 성광의료재단 | 전분화능 줄기세포에서 자연살해세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법 |
| WO2024224359A1 (en) * | 2023-04-27 | 2024-10-31 | Takeda Pharmaceutical Company Limited | Method for expanding cd56+/cd3- cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018737B1 (en) | 1979-04-11 | 1983-11-09 | Mitsui Petrochemical Industries, Ltd. | Process for producing spherical carrier particles for olefin polymerisation catalyst, catalyst comprising such carrier particles, and use of such catalyst in olefin polymerisation |
| EP0187371B1 (en) | 1984-12-27 | 1991-06-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituted isoquinolinesulfonyl compounds |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| EP0814838B1 (en) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Antigen presenting system and activation of t-cells |
| AU723355B2 (en) | 1996-05-23 | 2000-08-24 | Scripps Research Institute, The | MHC class II antigen presenting systems and methods for activating CD4+ T cells |
| AU5734998A (en) | 1997-01-10 | 1998-08-03 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| US6844354B1 (en) | 1999-03-25 | 2005-01-18 | Mitsubishi Pharma Corporation | Agent for prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis |
| AU5250400A (en) | 1999-06-18 | 2001-01-09 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| MXPA04007196A (es) | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| US6664266B2 (en) | 2002-03-14 | 2003-12-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitiors |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| US7393835B2 (en) | 2002-04-22 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase C |
| BRPI0514778B1 (pt) | 2004-09-08 | 2018-07-10 | Wisconsin Alumni Research Foundation | Meio para cultivar células tronco embrionárias |
| US7993638B2 (en) | 2006-03-01 | 2011-08-09 | Janssen Pharmaceutica Nv | Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| US8513012B2 (en) | 2008-05-02 | 2013-08-20 | Cellular Dynamics International, Inc. | Method for production of mast cells from stem cells |
| CN102388130B (zh) | 2009-02-27 | 2014-08-27 | 细胞动力国际有限公司 | 多能细胞的分化 |
| BR112012014104A2 (pt) * | 2009-12-04 | 2016-07-05 | Stem Cell & Regenerative Medicine International Inc | método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco |
| US9260696B2 (en) * | 2012-04-24 | 2016-02-16 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
-
2013
- 2013-04-23 US US13/868,785 patent/US9260696B2/en active Active
- 2013-04-23 AU AU2013251785A patent/AU2013251785B2/en not_active Ceased
- 2013-04-23 WO PCT/US2013/037782 patent/WO2013163171A1/en not_active Ceased
- 2013-04-23 EP EP19179319.9A patent/EP3567102A1/en not_active Withdrawn
- 2013-04-23 EP EP13720688.4A patent/EP2841563B1/en active Active
- 2013-04-23 JP JP2015509079A patent/JP6339998B2/ja active Active
-
2017
- 2017-06-13 JP JP2017115944A patent/JP6529541B2/ja active Active
-
2018
- 2018-07-18 AU AU2018206749A patent/AU2018206749A1/en not_active Abandoned
-
2019
- 2019-05-14 JP JP2019091121A patent/JP2019122415A/ja active Pending
-
2020
- 2020-11-06 AU AU2020264375A patent/AU2020264375B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7440027B2 (ja) | 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法 | |
| JP6529541B2 (ja) | 幹細胞よりナチュラルキラー細胞を発生させる方法 | |
| JP6948072B2 (ja) | Ｃｄ８陽性ｔ細胞を誘導する方法 | |
| CN102329769B (zh) | 一种获得造血干细胞的方法 | |
| Knorr et al. | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy | |
| Sun et al. | Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a production assistant for cell therapy (PACT) translational application | |
| CN107922925A (zh) | 用于自然杀伤细胞扩增的方法 | |
| US7811821B2 (en) | Method of forming dendritic cells from embryonic stem cells | |
| US20220411752A1 (en) | Method for producing t cells | |
| Ni et al. | Hematopoietic and nature killer cell development from human pluripotent stem cells | |
| TW201900872A (zh) | 高活性nk細胞及其利用 | |
| WO2015099134A1 (ja) | 再構成されたｔ細胞レセプター遺伝子を有する多能性幹細胞由来のｔ前駆細胞を用いる免疫細胞療法 | |
| KR102803233B1 (ko) | 조혈 전구 세포 마커 | |
| US11299709B2 (en) | Pluripotent stem cell and T cell differentiated therefrom and application thereof | |
| JPWO2016010153A1 (ja) | 免疫細胞療法用ｔ細胞の誘導方法 | |
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| KR101390613B1 (ko) | Ｓｅｌｅｎｉｕｍ을 이용한 인간 만능줄기세포의 혈액전구세포, 혈관전구세포, 내피세포 및 평활근세포로의 분화방법 | |
| Moon et al. | Differentiation of hESCs into mesodermal subtypes: vascular-, hematopoietic-and mesenchymal-lineage cells | |
| TW200540270A (en) | Medium for feeder-free differentiation and feeder-free differentiation method from primate embryonic stem cell | |
| WO2026100580A1 (ja) | エプスタイン・バー・ウイルス（ｅｂｖ）に対して特異的なｔ細胞 | |
| CN115418373A (zh) | 一种体液免疫系统再生的方法及其应用 | |
| Ma | Derivation of Lymphocytes from Human induced Pluripotent Stem Cells | |
| Gori et al. | Blood First Edition Paper, prepublished online August 16, 2012; DOI 10.1182/blood-2012-05-433797 | |
| EA045419B1 (ru) | Маркер гемопоэтических клеток-предшественников | |
| HK40020008A (en) | Hematopoietic progenitor cell marker |